ID
41345
Descripción
Study ID: 105043/013 Clinical Study ID: 105043/013 Study Title: An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin (Protocol SKF105043/013) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00039858 Sponsor: GlaxoSmithKline Collaborators: Encysive Pharmaceuticals Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Argatroban Trade Name: N/A Study Indication: Thrombosis This Study evaluates the safety and the efficacy of i.v. Argatroban treatment in paediatric patients which require anticoagulants but aren't suitable for Heparin treatment. The study consists of screening visit (pre-treatment examination), treatment period of maximum 14 days after reaching therapeutical dose, post-treatment visit (once the treatment is stopped or after 14 days) and a follow-up visit which follows 30 days (+/- 14 days) after clinical resolution of underlying condition or after the end of the 14-day study period. Treatment can be continued after the 14-day study period if needed but such treatment isn't part of this Study. See https://clinicaltrials.gov/ct2/show/NCT00039858 This Form has to be filled in at the screening visit after the Investigator decides whether Patient should be enrolled into the Study. Please fax GSK immediately after a patient is enrolled or failed the screen. Use the fax form provided. (fax form not included in CRF)
Link
https://clinicaltrials.gov/ct2/show/NCT00039858
Palabras clave
Versiones (2)
- 31/8/20 31/8/20 -
- 2/9/20 2/9/20 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
2 de septiembre de 2020
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Safety and Efficacy of Argatroban in Pediatric Patients, NCT00039858
Patient Enrollment / Screen Failure
- StudyEvent: ODM
Descripción
Patient Enrollment / Screen Failure
Alias
- UMLS CUI-1
- C4041024
- UMLS CUI-2
- C1710476
Descripción
*If No, check reason for patient not being enrolled into study:
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C2348568
- UMLS CUI [1,2]
- C1516879
- UMLS CUI [1,3]
- C0048470
Descripción
Eligibility Criteria not met
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C0231175
Descripción
Age stratification group full
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0441833
- UMLS CUI [1,2]
- C1514983
- UMLS CUI [1,3]
- C0001779
- UMLS CUI [1,4]
- C0443225
Descripción
Consent withdrawal
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1707492
Descripción
Other reason of screen failure
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C1710476
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C0205394
Descripción
Other reason of screen failure - specification
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C1710476
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C0205394
- UMLS CUI [1,4]
- C1521902
Similar models
Patient Enrollment / Screen Failure
- StudyEvent: ODM
C0019994 (UMLS CUI [1,2])
C1710476 (UMLS CUI-2)
C1516879 (UMLS CUI [1,2])
C0048470 (UMLS CUI [1,3])
C0231175 (UMLS CUI [1,2])
C1514983 (UMLS CUI [1,2])
C0001779 (UMLS CUI [1,3])
C0443225 (UMLS CUI [1,4])
C0566251 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])